2 min read
Cancer Research Trends | Key ASCO 2024 Takeaways
Discussion with Gabriela Rosu, MD, Sr. Director, Global Medical Affairs
2 min read
Discussion with Gabriela Rosu, MD, Sr. Director, Global Medical Affairs
3 min read
How Veristat’s Proven DMC Expertise for Complex Trials Supports Patient Safety and Sponsor Success
4 min read
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...
12 min read
4 min read
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...
3 min read
Clinical trial leaders in small and medium-sized biotech companies regularly find themselves at the intersection of growing requirements, shrinking timelines, and talent shortages. With organizational restructuring and staffing reductions continuing,...
2 min read
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...
1 min read
Learn how Veristat’s multidisciplinary team helped sponsors navigate the complexities of global regulatory submissions, achieving early and successful outcomes.
4 min read
In partnership with Clinical Leader, Veristat consulting, regulatory, and clinical experts gave a live webinar outlining how to better advance new cancer therapies in alignment with FDA’s Project FrontRunner. The webinar covered the following:
5 min read
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...